Community-acquired pneumonia: a US perspective on the guideline gap

J Antimicrob Chemother. 2024 May 2;79(5):959-961. doi: 10.1093/jac/dkae050.

Abstract

Community-acquired pneumonia continues to be one of the most common causes of morbidity and mortality due to infectious disease. The aetiologies, clinical presentations, diagnostic modalities and therapeutic options are changing and outpacing the creation of management guidelines. This educational article summarizes a roundtable activity sponsored by an unrestricted educational grant by Paratek that included US experts discussing these changes and identifying gaps in the current guidelines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Community-Acquired Infections* / diagnosis
  • Community-Acquired Infections* / drug therapy
  • Humans
  • Pneumonia* / diagnosis
  • Pneumonia* / drug therapy
  • Pneumonia* / therapy
  • Practice Guidelines as Topic*
  • United States

Substances

  • Anti-Bacterial Agents

Grants and funding